- Trials with a EudraCT protocol (79)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
79 result(s) found for: Chromatography.
Displaying page 1 of 4.
EudraCT Number: 2019-001066-15 | Sponsor Protocol Number: LR19912019 | Start Date*: 2019-08-16 | |||||||||||
Sponsor Name:Merete Hædersdal | |||||||||||||
Full Title: Treatment of hypertrophic scars using needle-free jet-injection of triamcinolone and 5-Fluorouracile: a prospective, controlled, randomized, single-blinded split-lesion trial. | |||||||||||||
Medical condition: Hypertrophic scars on 20 participants | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005098-28 | Sponsor Protocol Number: GTI1305 | Start Date*: 2015-01-16 | |||||||||||
Sponsor Name:Grifols Therapeutics LLC. | |||||||||||||
Full Title: A multicenter, prospective, open-label, non-controlled clinical trial to assess the efficacy and safety of Immune Globuline (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in patients with ... | |||||||||||||
Medical condition: Myasthenia Gravis Exacerbations | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) BE (Completed) RO (Completed) PL (Completed) EE (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002225-30 | Sponsor Protocol Number: 69HCL18_0957 | Start Date*: 2019-07-18 | ||||||||||||||||
Sponsor Name:Hospices Civils de Lyon | ||||||||||||||||||
Full Title: Impact of low protein diet supplemented with ketoanalogues on uremic toxins production and glucose metabolism in chronic kidney disease_KETO GUT study | ||||||||||||||||||
Medical condition: chronic kidney disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005099-17 | Sponsor Protocol Number: GTI1306 | Start Date*: 2015-07-07 | |||||||||||
Sponsor Name:Grifols Therapeutics Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/ chromatography Purified (lGIV -C) as a Corticosteroi... | |||||||||||||
Medical condition: Myasthenia Gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) EE (Completed) HU (Completed) CZ (Completed) DE (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004126-56 | Sponsor Protocol Number: NUTH-2005-03523 | Start Date*: 2006-03-07 |
Sponsor Name:Newcastle upon Tyne Hospitals NHS Trust | ||
Full Title: Observational pharmacokinetic study of doxorubicin and cyclophosphamide in patients with early breast cancer. | ||
Medical condition: Early breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003997-18 | Sponsor Protocol Number: GTI1408 | Start Date*: 2015-07-07 | |||||||||||
Sponsor Name:Grifols Therapeutics Inc. | |||||||||||||
Full Title: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/ Chromatography Purified (IGIV -C) in Symptomatic Su... | |||||||||||||
Medical condition: Myasthenia Gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) EE (Completed) HU (Completed) CZ (Completed) DE (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000542-20 | Sponsor Protocol Number: CLAF237A2338 | Start Date*: 2004-07-16 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: A Multicenter, Double-Blind, Randomized, Active Controlled Study to Compare the Effect of 52 Weeks Treatment with LAF237 50 mg bid to Gliclazide up to 320 mg Daily as Add-On Therapy in Patients wit... | |||||||||||||
Medical condition: treatment of type 2 diabetes in combination therapy with other anti-diabetic oral drugs | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) SK (Completed) ES (Completed) DK (Completed) CZ (Completed) HU (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000539-27 | Sponsor Protocol Number: CLAF237A2307 | Start Date*: 2004-09-08 |
Sponsor Name:Novartis Sverige AB | ||
Full Title: A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 52 Weeks Treatment with LAF237 50 mg qd to Placebo in Drug-Naïve Patients with Type 2 Diabetes and Mild Hyperg... | ||
Medical condition: Type 2 Diabetes | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) FI (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-001275-21 | Sponsor Protocol Number: IriGen | Start Date*: 2013-07-29 | |||||||||||
Sponsor Name:Centre Jean Perrin | |||||||||||||
Full Title: Phase II study: individualization of dosage of irinotecan in the FOLFIRI according to the genetic polymorphism of UGT1A1 in the first line treatment of metastatic colorectal cancer | |||||||||||||
Medical condition: first line metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001281-11 | Sponsor Protocol Number: 20CH065 | Start Date*: 2020-03-30 | ||||||||||||||||
Sponsor Name:CHU de Saint Etienne | ||||||||||||||||||
Full Title: Evaluation of the concentration/viral effect relationship of hydroxychloroquine in COVID-19 patients in the intensive care unit. | ||||||||||||||||||
Medical condition: covid-19 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001443-31 | Sponsor Protocol Number: 1801 | Start Date*: 2018-11-21 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: DOAC Levels prior to Incision study: DALI study | ||
Medical condition: No medical condition will be investigated. This study will only investigate DOAC levels during surgery. Patients who use DOACs are patients with venous thrombosis and atrial fibrillation. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001772-10 | Sponsor Protocol Number: 2016-06 | Start Date*: 2020-02-14 | |||||||||||
Sponsor Name:Assistance Publique-Hôpitaux de Marseille | |||||||||||||
Full Title: Phase I study of oral metronomic NAVELBINE® and HEMANGIOL®combination for children and teenagers with refractory/relapsing solid tumors | |||||||||||||
Medical condition: Pediatric Solid tumor | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000540-24 | Sponsor Protocol Number: CLAF237A2310 | Start Date*: 2004-12-15 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A multicenter, double-blind, randomized, active controlled study to compare the effect of long term treatment with LAF237 50 mg bid to gliclazide up to 320 mg daily in drug naïve patients with type... | ||
Medical condition: Type II Diabetes | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) IE (Completed) GB (Completed) DE (Completed) IT (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-000156-18 | Sponsor Protocol Number: 301OTC02 | Start Date*: 2018-08-15 | |||||||||||
Sponsor Name:Ultragenyx Pharmaceutical, Inc. | |||||||||||||
Full Title: A Long-Term Follow-up Study to Evaluate the Safety and Efficacy of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults with Lat... | |||||||||||||
Medical condition: Ornithine transcarbamylase deficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Trial now transitioned) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005254-68 | Sponsor Protocol Number: GEL/TAMO-2006 | Start Date*: 2007-04-13 |
Sponsor Name:GEL/TAMO (Cooperative Spanish Group of Lymphoma/Autologous bone marrow transplant). | ||
Full Title: Treatment with R-MegaCHOP and early rescue with R-IFE and autologous stem cells transplant (ASCT) according response measured by positron emission tomography (PET) in patients with diffuse large B-... | ||
Medical condition: Diffuse Large B-Cell Lymphoma (DLBCL) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-002342-11 | Sponsor Protocol Number: D1449L00033 | Start Date*: 2007-04-19 |
Sponsor Name:Klinikum Fulda gAG | ||
Full Title: Multicenter study of neurotransmitters and neuropeptides in schizophrenia: A multidisciplinary study of biological, pharmacokinetic, receptor occupancy and clinical relationships in patients suffer... | ||
Medical condition: Patients have to fulfill the diagnostic criteria of a schizophrenia according to DSM-IV. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-006866-27 | Sponsor Protocol Number: 1160.88 | Start Date*: 2012-03-15 | |||||||||||
Sponsor Name:Boehringer Ingelheim (Canada) Ltd./Ltée | |||||||||||||
Full Title: Open-label safety and tolerability study of dabigatran etexilate given for 3 days at the end of standard anticoagulant therapy in children aged 12 years to less than 18 years | |||||||||||||
Medical condition: Venous Thrombotic Event | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005717-36 | Sponsor Protocol Number: 1645-CI-057 | Start Date*: 2012-06-14 |
Sponsor Name:Instituto de Investigación Sanitaria La Fe | ||
Full Title: Extremely low gestational age neonates randomly an assigned to be blindly resuscitated with 21% vs. 60% oxygen: influence upon mortality and chronic conditions in the neonatal period. | ||
Medical condition: Preterm infants aged 30 weeks or less, who need resuscitation / stabilization maneuvers with positive pressure ventilation immediately after birth | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003537-15 | Sponsor Protocol Number: TXA2018 | Start Date*: 2019-02-18 | ||||||||||||||||
Sponsor Name:Medical University Vienna | ||||||||||||||||||
Full Title: Different dosing of Tranexamic Acid in patients undergoing elective total hip or knee arthroplasty. A randomized, controlled, double-blinded clinical trial. | ||||||||||||||||||
Medical condition: Blood loss in patients undergoing elective total hip or knee arthroplasty. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012039-14 | Sponsor Protocol Number: FOR2009-JE | Start Date*: 2009-05-25 | |||||||||||
Sponsor Name:Respiratory and Allergy Research Unit | |||||||||||||
Full Title: Blood- and urinary concentrations of inhaled formoterol in asthmatic subjects and elite asthletes with asthma. | |||||||||||||
Medical condition: The purpose of this study i to assess the serum and urine concentrations of inhaled formoterol and evaluate the difference in three groups: healthy men, male asthmatic subjects and male elite athle... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
